Found 126 clinical trials
Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer
prostate cancer; specifically, men with a histopathologic diagnosis of Grade Group 2 & 3, with prostate specific antigen level <20 ng/mL. And to assess the safety of the combination treatment
- 0 views
- 29 Aug, 2023
- 1 location
Dose De-escalation in Prostate Radiotherapy Using the MRL (DESTINATION)
toxicity in the acute and late setting post radiotherapy as well as Prostate-Specific antigen (PSA) control up until 2 years post treatment. Participants will be treated with radiotherapy to the
- 0 views
- 16 Sep, 2023
- 1 location
MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
prostate-specific antigen (PSA) to < 0.1 ng/mL), which is related to long-term outcome biochemically. Biomarker expression levels differ in the DCE-MRI enhancing and non-enhancing tumor
- 23 views
- 15 Dec, 2021
- 1 location
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
radiation will get rid of the cancer from participants' prostates and reduce their prostate-specific antigen (PSA) to an undetectable level.
- 140 views
- 07 Jul, 2022
- 11 locations
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer (PROMPT)
the surgical procedure. The failure rate is even more pronounced in those patients that present with high prostate specific antigen (PSA) levels, pT3 disease, positive margins and Gleason score 8 with
- 3 views
- 25 Feb, 2022
- 2 locations
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
elevated serum prostate-specific antigen (PSA) level and/or abnormal digital rectal examination (DRE). It is estimated that more than 1 million TRUS-guided prostate biopsies are performed annually in the
- 13 views
- 21 Mar, 2022
- 1 location
Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer (PLUTO)
features where the risk may be even higher. Recurrence typically manifests as a rise in serum-level of prostate-specific antigen (PSA), referred to as biochemical recurrence. Post-operative radiotherapy is
- 2 views
- 02 Mar, 2022
- 1 location
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer (HIFUSA)
examination, PSA (Prostate-Specific Antigen) assay. Active surveillance remains difficult to manage psychologically for both the patient and the practitioner, because of the lack of treatment on the one hand
- 5 views
- 14 Feb, 2022
- 12 locations
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
deficiency and/or microsatellite instability. For men who previously received definitive treatment for prostate cancer and subsequently develop detectable prostate specific antigen (PSA) levels, the
- 6 views
- 06 May, 2022
- 1 location
Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer
Less than 50% of patients receiving salvage radiation therapy (SRT) to the pelvis as treatment for prostate cancer relapsing after surgery will achieve undetectable Prostate Specific Antigen
- 0 views
- 01 Oct, 2021
- 5 locations